Overview of Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Guillermo Garcia-Manero, MD, provides a brief overview of lower-risk myelodysplastic syndromes (LR-MDS).
Video content above is prompted by the following questions:
- Provide a brief overview of lower-risk myelodysplastic syndromes (LR-MDS)?
- What are the clinical hallmarks of LR-MDS?
- As anemia is present in >90% of cases, what are available therapies to alleviate anemia?
Recent Videos
Related Content
COMMANDS Trial Demonstrates Benefit Across Mutations in RS-Positive LR-MDS
October 23rd 2024Article
During a Case-Based Roundtable® event, Yazan Madanat, MD, discussed a the patient population and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.
Read More
Lunning Evaluates CAR T-Cell Therapy for ASCT-Eligible and Ineligible DLBCL
September 22nd 2024Article
During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen receptor T-cell therapies in patients with diffuse large B-cell lymphoma.
Read More
